SPRY | Ticker Profile - Titan Protect

SPRY

ARS Pharmaceuticals, Inc.

Healthcare · Biotechnology · NGM

$8.56

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$844M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-8.92

Based on estimated future earnings — lower means cheaper

Rev Growth

+184.5%

Year-over-year revenue change

Profit Margin

-200.0%

How much profit the company keeps from each dollar of revenue

ROE

-136.4%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$25.00

+192% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 5 analysts covering this stock

About ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

https://ars-pharma.com

Country: United States Employees: 154 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.381

Positive but modest risk-adjusted returns

Kelly Fraction

0.0202

Modest edge detected — smaller position warranted

Calmar Ratio

0.051

Drawdown risk outweighs the returns — higher risk profile

Annual Return

3.3%

Historical annualised return based on price data

Max Drawdown

-63.3%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.80

Less volatile than the market — more defensive

52W High

$18.90

55% below the year high

52W Low

$6.66

29% above the year low

Avg Volume

1,662,178

Average daily shares traded — higher means easier to buy and sell

Short Ratio

13.9

Days it would take all short sellers to cover — higher means more crowded

Short % Float

37.7%

Very high short interest — potential squeeze candidate

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-2.00

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

279.24

Heavy leverage — higher financial risk if revenues decline

Current Ratio

4.94

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

4.65

Like current ratio but excludes inventory — stricter test

Gross Margin

59.4%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-265.2%

Profit from core operations before interest and tax

Free Cash Flow

$-98,275,000

Negative — the business is spending more than it generates

Revenue (TTM)

$99M

Total revenue over the last 12 months

Net Income

$-197,976,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$32.00

Target Median

$25.00

Target Low

$12.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go